Sign In

CEO of CMA’s newest subsidiary named

A veteran in running not-for-profit health organizations in Canada has been appointed as the Chief Executive Officer (CEO) of the CMA’s newest subsidiary.

The announcement of Lindee E. David as CEO of 872147 Canada Inc. (NewCo) was made by Dr. Brian Brodie, chair of the CMA Board of Directors.

“With extensive experience in the not-for-profit and corporate sectors and with a proven track record of achieving business results in an ever-evolving health care market, all of us at the CMA look forward to welcoming Ms. David,” said Dr. Brodie, in making the announcement.

David’s portfolio includes new product introduction, knowledge and clinical products formerly managed by the CMA including CMAJ and other CMA Publications and CMA’s Conjoint Accreditation Program.

David joins the CMA from Crohn’s and Colitis Canada where she served as CEO. Prior to joining Crohn’s and Colitis Canada, she held positions with, among others, the ALS Society of Canada, Janssen Ortho, a division of Johnson and Johnson, Canadian Blood Services and the Canadian Hemophilia Society. As executive director of the Canadian Hemophilia Society in the 1990s, David advocated on behalf of recipients of blood and blood products resulting in the largest-ever government settlement for those with infected with contaminated blood.

“These are exciting times and we are confident that under Ms. David’s leadership, our newest subsidiary will offer our members new benefits and greater value,” said Brodie.

Creation of the new subsidiary was approved unanimously by the CMA Board last summer to address a number of strategic opportunities and to accurately reflect the CMA’s value proposition of advocacy, knowledge and financial products and services.”

In her role as NewCo. CEO, David will work closely with Tim Smith, CEO of CMA and Brian Peters, CEO of MD Financial Management.

Forward any comments about this article to: cmanews@cma.ca.